Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes

BackgroundWhen a patient experiences an event other than the one of interest in the study, usually the probability of experiencing the event of interest is altered. By contrast, disease-free survival time analysis by standard methods, such as the Kaplan-Meier method and the standard Cox model, does not distinguish different causes in the presence of competing risks. Alternative approaches use the cumulative incidence estimator by the Cox models on cause-specific and on subdistribution hazards models. We applied cause-specific and subdistribution hazards models to a diabetes dataset with two competing risks (end-stage renal disease (ESRD) or death without ESRD) to measure the relative effects of covariates and cumulative incidence functions.ResultsIn this study, the cumulative incidence curve of the risk of ESRD by the cause-specific hazards model was revealed to be higher than the curves generated by the subdistribution hazards model. However, the cumulative incidence curves of risk of death without ESRD based on those three models were very similar.ConclusionsIn analysis of competing risk data, it is important to present both the results of the event of interest and the results of competing risks. We recommend using either the cause-specific hazards model or the subdistribution hazards model for a dominant risk. However, for a minor risk, we do not recommend the subdistribution hazards model and a cause-specific hazards model is more appropriate. Focusing the interpretation on one or a few causes and ignoring the other causes is always associated with a risk of overlooking important features which may influence our interpretation.

[1]  S. Satchell,et al.  Diabetic nephropathy. , 2012, Clinical medicine.

[2]  D. Kleinbaum,et al.  Survival Analysis: A Self-Learning Text. , 1996 .

[3]  Martin Schumacher,et al.  Misspecified regression model for the subdistribution hazard of a competing risk by Latouche A, Boisson V, Chevret S and Porcher R. Statistics in Medicine 2006; DOI: 10.2002/sim.2600 , 2007, Statistics in medicine.

[4]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[5]  B. Stengel,et al.  Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). , 2005, Kidney international.

[6]  S. Cole,et al.  Competing risk regression models for epidemiologic data. , 2009, American journal of epidemiology.

[7]  Melania Pintilie,et al.  Analysing and interpreting competing risk data , 2007, Statistics in medicine.

[8]  D. Cox Regression Models and Life-Tables , 1972 .

[9]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[10]  Joseph Cavanaugh,et al.  Probability and Random Variables , 1999, Mathematical Modelling.

[11]  R. DeFronzo Diabetic nephropathy: Etiologic and therapeutic considerations , 1995 .

[12]  D. Lin,et al.  Non-parametric inference for cumulative incidence functions in competing risks studies. , 1997, Statistics in medicine.

[13]  Mei-Jie Zhang,et al.  SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models , 2011, Comput. Methods Programs Biomed..

[14]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[15]  Nathaniel Osgood,et al.  Epidemiology of diabetes mellitus among First Nations and non-First Nations adults , 2010, Canadian Medical Association Journal.

[16]  R. Light,et al.  Competing Risk Factor Analysis of End-Stage Renal Disease and Mortality in Chronic Kidney Disease , 2008, American Journal of Nephrology.

[17]  H. Bilo,et al.  Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: A prospective population-based study in The Netherlands (ZODIAC-1) , 2002, European Journal of Epidemiology.

[18]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[19]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[20]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[21]  M. Harris,et al.  Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971–1993 , 1998, Diabetes Care.

[22]  R. DeFronzo,et al.  The natural history of diabetic nephropathy. , 1990, Seminars in nephrology.

[23]  E. Friedman Natural History of Diabetic Nephropathy , 1986 .

[24]  John P Klein,et al.  Modelling competing risks in cancer studies , 2006, Statistics in medicine.

[25]  Mei-Jie Zhang,et al.  Summarizing differences in cumulative incidence functions , 2008, Statistics in medicine.

[26]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[27]  K. Bloch,et al.  Mortality and predictors of mortality in a cohort of Brazilian type 2 diabetic patients. , 2004, Diabetes care.

[28]  W. D. Ray 4. Modelling Survival Data in Medical Research , 1995 .

[29]  Jeffrey J. Gaynor,et al.  On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data , 1993 .

[30]  J. Nagy,et al.  Prevention and treatment of diabetic nephropathy. , 2005, Diabetes research and clinical practice.

[31]  Martin Schumacher,et al.  A competing risks analysis of bloodstream infection after stem‐cell transplantation using subdistribution hazards and cause‐specific hazards , 2007, Statistics in medicine.

[32]  Martin Schumacher,et al.  Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified , 2010, Statistics in medicine.

[33]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[34]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[35]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[36]  J. Mau,et al.  On a Graphical Method for the Detection of Time‐Dependent Effects of Covariates in Survival Data , 1986 .

[37]  William A Ghali,et al.  Kaplan-Meier methods yielded misleading results in competing risk scenarios. , 2006, Journal of clinical epidemiology.

[38]  V. Sørensen,et al.  Improved survival rate in patients with diabetes and end-stage renal disease in Denmark , 2007, Diabetologia.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  R. Gray A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[41]  J. Fine,et al.  Parametric regression on cumulative incidence function. , 2007, Biostatistics.

[42]  Walter R. Young,et al.  The Statistical Analysis of Failure Time Data , 1981 .

[43]  W. J. Johnson,et al.  Survival rates of 2,728 patients with end-stage renal disease. , 1984, Mayo Clinic proceedings.

[44]  D Machin,et al.  Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches , 2001, Statistics in medicine.

[45]  R. Écochard,et al.  The Impact of Type 2 Diabetes on Mortality in End-Stage Renal Disease Patients Differs between Genders , 2009, Nephron Clinical Practice.

[46]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[47]  E. Scott Modelling Survival Data in Medical Research , 1995 .

[48]  T. Craven,et al.  Racial differences in the incidence of end-stage renal disease. , 1996, Ethnicity & health.

[49]  C. Abrass Kidney Disease in Diabetes , 2004 .